Development

OUR
PIPELINE

We are developing commercial-scale production technologies for diagnostic and therapeutic radioisotopes, increasingly important options for the diagnosis and treatment of serious disease.

Our Programs

Committed to helping patients, NorthStar is advancing a broad portfolio of radiopharmaceuticals for use in therapeutic and diagnostic applications.

Development Scale
Engineering & Chemistry
Proof of Concept
Scale-Up
Data Development
FDA REVIEW
APPROVAL
molybdenum-99 Parent isotope of Tc-99m, the most widely used medical isotope used to diagnose and stage heart disease, cancer, infection, inflammation and other conditions.
COPPER-67 Treatment of a wide variety of adult and childhood cancers including neuroendocrine tumors, neuroblastoma, glioma, lymphoma, etc.
actinium-225 Used in targeted alpha therapy for the treatment of certain forms of cancer, including; leukemia, prostate, brain and neuroendocrine tumors
NMT-009

In-LICENSED PRODUCTS

Development Scale
Engineering & Chemistry
Proof of Concept
Scale-Up
Data Development
FDA REVIEW
APPROVAL
FibroScint Thrombus imaging in patients with mechanical assist device

COLLABORATIONS

Development Scale
Engineering & Chemistry
Proof of Concept
Scale-Up
Data Development
FDA REVIEW
APPROVAL
Monopar Treatment of hyperinflammatory disease
IODINE-123 CAPSULES Diagnosis of thyroid disease
IBA Mo-99 This collaboration is aimed at establishing NorthStar’s accelerator Mo-99 (aMo-99) production capabilities outside of the U.S.